Post-Menopause Osteoporosis: Oral or Venous Treatment?

Abstract: Patients with high risk of fragilty fractures, and those with recent fractures, should receive the highest priority for anti-osteoporotic treatment due to the severe consequences (morbidity and mortality of some of these fractures Chip, vertebrae, pelvis and humerus). The duration of treatment should be based on the assessment of fracture risk. This work used as a methodology a literature review by searching the PubMED database between 2009 and 2019 with the keywords: "osteoporosis", “zoledronic acid", "alendronate sodiurn", "cost analysis effectiveness"," health economics ". In this study, we can see that the most cost-effective postmenopausal anti-osteoporotic therapy should use oral Alendronate sodium or generic parenteral zoledronic acid. The choice of the ideal treatment should be based on the side effects of medications or by medication adherence. Considcnng the advantage of dosage convenience and treatment adherence with annual use of parenteral zoledronic acid, this drug may be a cost-effective treatment option compared with oral alendronate. KEYWORDS: Cost-effectiveness analysis, Health economics, Osteoporosis, Zoledronic acid, Alendronate.